YOU ARE INVITED TO
From Molecule to Medicine: The Clinical Trial Pathway
DATE & TIME
January 26th, 9am PST | 12pm EST
Clearmind’s Management Team Will Explain the Process Required by the FDA to Approve Clearmind’s Patented MEAI Molecule as a Medicine for Treating Alcohol Use Disorder and Binge Drinking
Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.
Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.
Shannon has interviewed some of the most prominent leaders, innovators, scientists, doctors and luminaries in the psychedelic space. She was the host of Seasons 1 & 2 of ‘Examining The Psychedelic Renaissance’ with MAPS Canada. Shannon has researched, observed, coached and trained in excess of 5,000 individuals in sales, marketing, and business management and continues to help people through her company Insight Global, and enjoys interviewing leaders in the health and wellness field through her podcast ‘Dialed In’.